UBS raised the firm’s price target on Tenet Healthcare (THC) to $238 from $230 and keeps a Buy rating on the shares. Tenet’s Q2 adjusted EBITDA was ahead of consensus by $125M, while the acute segment beat by $110M and the United Surgical Partners International segment was $15M ahead, the analyst tells investors in a research note. While uncertainty around the exchanges and Medicaid policy changes are a concern for hospitals, the firm expects USPI to continue delivering strong organic and inorganic growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $225 from $210 at Morgan Stanley
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare: Strategic Focus and Financial Performance Drive Buy Rating
- Tenet Healthcare Reports Strong Q2 2025 Earnings, Raises Outlook
- Tenet Healthcare’s Earnings Call Highlights Robust Growth